
**Assessment of the safety of magnetic
resonance imaging for patients with
an active implantable medical device**

*Évaluation de la sécurité de l'imagerie par résonance magnétique
pour les patients avec un dispositif médical implantable actif*

iTeh Standards
(<https://standards.iteh.ai>)
Document Preview

[ISO/TS 10974:2018](https://standards.iteh.ai/catalog/standards/iso/f2ca77ee-1fca-4ef8-b8cf-70deb5f9a30c/iso-ts-10974-2018)

<https://standards.iteh.ai/catalog/standards/iso/f2ca77ee-1fca-4ef8-b8cf-70deb5f9a30c/iso-ts-10974-2018>



iTeh Standards
(<https://standards.iteh.ai>)
Document Preview

[ISO/TS 10974:2018](https://standards.iteh.ai/catalog/standards/iso/f2ca77ee-1fca-4ef8-b8cf-70deb5f9a30c/iso-ts-10974-2018)

<https://standards.iteh.ai/catalog/standards/iso/f2ca77ee-1fca-4ef8-b8cf-70deb5f9a30c/iso-ts-10974-2018>



COPYRIGHT PROTECTED DOCUMENT

© ISO 2018

All rights reserved. Unless otherwise specified, or required in the context of its implementation, no part of this publication may be reproduced or utilized otherwise in any form or by any means, electronic or mechanical, including photocopying, or posting on the internet or an intranet, without prior written permission. Permission can be requested from either ISO at the address below or ISO's member body in the country of the requester.

ISO copyright office
CP 401 • Ch. de Blandonnet 8
CH-1214 Vernier, Geneva
Phone: +41 22 749 01 11
Fax: +41 22 749 09 47
Email: copyright@iso.org
Website: www.iso.org

Published in Switzerland

Contents

	Page
Foreword.....	vii
Introduction.....	viii
1 Scope.....	1
2 Normative references.....	1
3 Terms and definitions.....	1
4 Symbols and abbreviated terms.....	6
5 General requirements for non-implantable parts.....	6
6 Requirements for particular AIMDs.....	6
7 General considerations for application of the tests of this document.....	6
7.1 Compliance criteria.....	6
7.2 Use of tiers.....	7
7.3 Test reports.....	7
7.3.1 General.....	7
7.3.2 Description of the AIMD under test.....	7
7.3.3 Test methods and results.....	7
8 Protection from harm to the patient caused by RF-induced heating.....	8
8.1 Introduction.....	8
8.2 Outline of the Stage 1 four-tier approach.....	8
8.3 Measurement system prerequisites for all tiers.....	10
8.3.1 RF field source.....	10
8.3.2 Tissue simulating phantom.....	10
8.3.3 Definition of power deposition.....	12
8.3.4 Measurement system validation.....	12
8.4 Determination of RF-induced power deposition in a tissue simulating medium.....	12
8.4.1 General.....	12
8.4.2 Determine location of hot spots around the AIMD.....	13
8.4.3 Determination of spatial (3D) distribution of power deposition for each hot spot.....	13
8.4.4 Determine the final power deposition.....	14
8.5 Proximity effect of electrodes from multiple leads.....	16
8.6 Modelling prerequisites for Tier 2, Tier 3, and Tier 4.....	17
8.7 Tier selection for RF-induced power deposition.....	17
8.7.1 General.....	17
8.7.2 Tier 1.....	17
8.7.3 Tier 2.....	18
8.7.4 Tier 3.....	19
8.7.5 Tier 4.....	20
8.8 <i>In vitro</i> model validation.....	21
8.9 Overall uncertainty analysis.....	23
8.10 <i>In vivo</i> analysis of power deposition.....	24
8.11 RF-induced heating assessment flow chart.....	24
9 Protection from harm to the patient caused by gradient-induced device heating.....	27
9.1 Introduction.....	27
9.2 Testing considerations.....	28
9.2.1 General.....	28
9.2.2 Determination of $ dB/dt $ rms exposure limits.....	29
9.2.3 Determination of test duration.....	29
9.3 Test requirements.....	29
9.3.1 General.....	29
9.3.2 <i>In vitro</i> test phantom or other suitable container.....	30
9.3.3 Gelled solution.....	30

9.3.4	Temperature survey to determine orientation and hot spots	30
9.3.5	Minimum temperature instrumentation	31
9.3.6	Definition of dB/dt test waveform	31
9.3.7	Characterization of applied dB/dt	32
9.4	Lab testing using simulated MR gradient field	32
9.5	MR scanner testing	32
9.6	Analysis of gradient heating test	33
10	Protection from harm to the patient caused by gradient-induced vibration	33
10.1	Introduction	33
10.2	Overview of tiers	34
10.3	MR environmental conditions	35
10.3.1	General	35
10.3.2	Determination of maximum clinical dB/dt	35
10.3.3	Determination of clinical B_0	35
10.3.4	Determination of clinical $dB/dt \times B_0$	35
10.3.5	Test frequencies	35
10.3.6	Test duration	36
10.3.7	Test temperature	37
10.4	General test procedure	37
10.4.1	Measurement of gradient field and determination of AIMD location	37
10.4.2	AIMD/test unit setup	37
10.5	Method 1 — MR scanner	38
10.6	Method 2 — Shaker table	39
10.6.1	General	39
10.6.2	Determine scanner input	39
10.6.3	AIMD vibration response	39
10.6.4	Determine shaker table amplitude (dB/dt scaling)	40
10.6.5	Perform vibration exposure using a shaker table	40
11	Protection from harm to the patient caused by B_0-induced force	41
12	Protection from harm to the patient caused by B_0-induced torque	41
13	Protection from harm to the patient caused by gradient-induced extrinsic electric potential	41
13.1	Introduction	41
13.2	General requirements	42
13.3	Gradient pulse leakage test	46
13.3.1	General	46
13.3.2	Test equipment	46
13.3.3	Test signal	46
13.3.4	Tier 1 — Combined gradient-induced charge measurement test procedure	48
13.3.5	Tier 2 — Separate transient gradient-induced charge and steady-state current measurement test procedure	51
13.4	Gradient rectification test	53
13.4.1	General	53
13.4.2	Test equipment	53
13.4.3	Test signal	53
13.4.4	Gradient-induced rectification measurement test procedure	54
13.5	Gradient pulse distortion of AIMD output test	56
13.5.1	General	56
13.5.2	Test equipment	56
13.5.3	Test signal	56
13.5.4	Gradient-induced AIMD output distortion test procedure	56
14	Protection from harm to the patient caused by B_0-induced malfunction	58
14.1	Introduction	58
14.2	Static field testing	59
14.2.1	B_0 general requirements for static field testing	59
14.2.2	B_0 field generation	60

14.2.3	Test conditions	60
14.3	Test procedures	60
14.3.1	General	60
14.3.2	Class 0 test procedure	60
14.3.3	Class 1 test procedure	60
14.3.4	Class 2 test procedure	61
15	Protection from harm to the patient caused by RF-induced malfunction and RF rectification	61
15.1	Introduction	61
15.2	General requirements	61
15.3	Mechanisms for RF interaction with an AIMD	61
15.4	Selecting radiated vs injected test methods	63
15.4.1	General	63
15.4.2	AIMD type designation for test method selection	63
15.4.3	RF antenna type designation for test method selection	65
15.4.4	RF EMC tier selection	65
15.4.5	RF test conditions	65
15.4.6	B_0 considerations	68
15.5	Injected immunity test	68
15.5.1	General	68
15.5.2	Determination of peak and rms injected levels for Tier 1 and Tier 2 — AIMD with short electrical length	69
15.5.3	Determination of peak and rms injected levels for Tier 3 and Tier 4	69
15.5.4	Injected immunity test procedure	71
15.5.5	RF phase test conditions	71
15.5.6	AIMD monitoring during the test	72
15.6	Radiated immunity test	72
15.6.1	General	72
15.6.2	Determining the RF radiated field level	72
15.6.3	Radiated test procedure	72
15.6.4	AIMD monitoring during the test	73
15.7	Test equipment	73
15.7.1	Generating the RF electric field for radiated testing (AIMD with short electrical length)	73
15.7.2	Phantom and tissue simulating medium for radiated testing	73
15.7.3	AIMD monitoring apparatus	73
15.7.4	RF level measuring device	74
15.7.5	RF injection network	74
15.8	Determining the peak RF injected level using a radiated test	75
16	Protection from harm to the patient caused by gradient-induced malfunction	76
16.1	Introduction	76
16.2	General requirements	76
16.3	Selecting radiated and injected test methods	77
16.4	Radiated immunity test	78
16.4.1	General	78
16.4.2	Test equipment	78
16.4.3	Radiated test signal	79
16.4.4	Test procedure	81
16.5	Injected immunity test	82
16.5.1	General	82
16.5.2	Test equipment	82
16.5.3	Injected test signal	82
16.5.4	Test procedure	84
16.5.5	AIMD test configuration	86
17	Combined fields test	93
17.1	Introduction	93
17.2	Test setup	94

17.3	AIMD fixation.....	96
17.4	Test procedure.....	97
17.4.1	General.....	97
17.4.2	Before MR exposure.....	97
17.4.3	During MR exposure.....	97
17.4.4	After MR exposure.....	97
17.5	Test equipment.....	97
17.5.1	Field generation.....	97
17.5.2	Phantom and tissue simulating medium.....	97
17.5.3	AIMD monitoring apparatus.....	98
18	Markings and accompanying documentation.....	98
18.1	Definitions.....	98
18.2	Applicability of labelling requirements.....	98
18.3	Labelling requirements.....	98
Annex A	(normative) Pulsed gradient exposure for Clause 10, Clause 13, and Clause 16.....	100
Annex B	(informative) Derivation of lead length factor for injected voltage test levels for Clause 13 and Clause 16.....	112
Annex C	(informative) Tier 1 high tangential E-field trough line resonator.....	121
Annex D	(informative) Supporting information and rationale for gradient-induced device heating.....	128
Annex E	(informative) Example RF injection network.....	133
Annex F	(informative) Supporting information and rationale for MR-induced vibration.....	135
Annex G	(informative) Gradient vibration patent declaration form.....	139
Annex H	(informative) Assessment of dielectric and thermal parameters.....	141
Annex I	(informative) RF exposure system validation method.....	146
Annex J	(informative) MR scanner RF transmit coil.....	156
Annex K	(informative) Current distribution on the AIMD as a function of the phase distribution of the incident field.....	158
Annex L	(informative) Tissue simulating medium formulations.....	161
Annex M	(informative) Generation of incident fields.....	165
Annex N	(informative) Dielectric and thermal tissue properties.....	180
Annex O	(informative) Gradient field injected testing — AIMD electrode tissue impedance determination method.....	184
Annex P	(informative) Estimation of conservative B_1 and 10 g averaged E-field values for Tier 1 for RF-induced heating and RF malfunction.....	189
Annex Q	(informative) AIMD configuration.....	197
Annex R	(informative) Electrically excitable tissue stimulation, terms and definitions.....	198
Annex S	(informative) Combined fields test.....	200
Annex T	(informative) General methods for modelling dB/dt levels in MR gradient coils.....	206
	Bibliography.....	212

Foreword

ISO (the International Organization for Standardization) is a worldwide federation of national standards bodies (ISO member bodies). The work of preparing International Standards is normally carried out through ISO technical committees. Each member body interested in a subject for which a technical committee has been established has the right to be represented on that committee. International organizations, governmental and non-governmental, in liaison with ISO, also take part in the work. ISO collaborates closely with the International Electrotechnical Commission (IEC) on all matters of electrotechnical standardization.

The procedures used to develop this document and those intended for its further maintenance are described in the ISO/IEC Directives, Part 1. In particular the different approval criteria needed for the different types of ISO documents should be noted. This document was drafted in accordance with the editorial rules of the ISO/IEC Directives, Part 2 (see www.iso.org/directives).

Attention is drawn to the possibility that some of the elements of this document may be the subject of patent rights. ISO shall not be held responsible for identifying any or all such patent rights. Details of any patent rights identified during the development of the document will be in the Introduction and/or on the ISO list of patent declarations received (see www.iso.org/patents).

Any trade name used in this document is information given for the convenience of users and does not constitute an endorsement.

For an explanation on the voluntary nature of standards, the meaning of ISO specific terms and expressions related to conformity assessment, as well as information about ISO's adherence to the World Trade Organization (WTO) principles in the Technical Barriers to Trade (TBT) see the following URL: www.iso.org/iso/foreword.html.

This document was prepared jointly by Technical Committee ISO/TC 150, *Implants for surgery*, Subcommittee SC 6, *Active implants*, and Technical Committee IEC TC 62, *Electrical equipment in medical practice*, Subcommittee SC 62B, *Diagnostic imaging equipment*. The draft was circulated for voting to the national bodies of both ISO and IEC.

This second edition cancels and replaces the first edition (ISO/TS 10974:2012) which has been technically revised.